Finance
UK Medical Products Maker Convatec Lifts Medium‑term Revenue Growth Target
Published by Global Banking & Finance Review®
Posted on February 24, 2026
2 min readLast updated: April 2, 2026
Add as preferred source on Google
Tags:healthcare
Quick Summary
Convatec lifted its medium‑term organic growth target to 6–8% after a 12% rise in adjusted operating profit to $544m. Guidance for 2026 remains 5–7% organic sales growth, excluding InnovaMatrix, with tariffs and product mix likely to temper H1.
Convatec Raises Medium‑Term Organic Revenue Target on Strong Pipeline
Convatec Growth Outlook and Financial Highlights
Feb 24 (Reuters) - Convatec lifted its medium-term organic revenue growth target on Tuesday, citing a strengthening medical product pipeline, after the British company posted a more than 12% rise in annual adjusted operating profit.
North America and Europe Focus
Advanced Wound Care Launches
Chronic Care Strategy and Expansion
The firm has pivoted into a pure-play chronic care company by streamlining its operations and launching new products, such as advanced wound care dressing, while expanding in North America and Europe.
Tariff Headwinds
InnovaMatrix Revenue Drag
Margin and Cost Outlook
Convatec expects its first-half adjusted operating margin to grow slightly from a year earlier, though lower revenue from its InnovaMatrix skin‑graft product and incremental tariff costs will likely weigh on its performance.
Adjusted Operating Profit Performance
The company, which also makes catheters and drug delivery systems, reported an annual adjusted operating profit of $544 million, compared with $485 million a year earlier, with steady demand in its chronic‑care portfolio and new product launches supporting the growth.
FY2026 Organic Sales Guidance
Medium‑Term Revenue Target Raised
The company reiterated that organic sales would grow 5% to 7%, excluding InnovaMatrix, for fiscal 2026. Convatec now sees its medium‑term organic revenue growth in the range of 6% to 8% compared with 5%–7% previously expected.
Reporting and Editing Credits
(Reporting by Nithyashree R B in Bengaluru; Editing by Mrigank Dhaniwala and Subhranshu Sahu)
Key Takeaways
- •Convatec raised its medium‑term organic revenue growth target to 6%–8% from 5%–7%.
- •Adjusted operating profit rose about 12% to $544 million year over year.
- •First‑half margin seen slightly higher, but InnovaMatrix weakness and tariffs may weigh.
- •Company reiterates 5%–7% organic sales growth for fiscal 2026, excluding InnovaMatrix.
- •Strategy focuses on chronic‑care products and expansion across North America and Europe.
References
Frequently Asked Questions about UK medical products maker Convatec lifts medium‑term revenue growth target
1What is the main topic?
Convatec increased its medium‑term organic revenue growth target to 6%–8% after reporting a double‑digit rise in adjusted operating profit, supported by a stronger product pipeline.
2How did Convatec perform financially?
Adjusted operating profit rose to about $544 million from $485 million a year earlier, reflecting steady demand in chronic‑care products and new launches.
3What guidance did the company reaffirm for 2026?
Convatec reiterated organic sales growth of 5%–7% for fiscal 2026 when excluding InnovaMatrix.